Carulli Michael 4

What Happened

• Michael Carulli, Chief Financial Officer of PMV Pharmaceuticals (PMVP), was granted a derivative award of 240,000 shares on March 5, 2026. The Form 4 reports the acquisition at $0.00 (derivative security), so no cash was paid in this reported transaction.
• Per the filing footnote, the award is subject to a time-based vesting schedule: shares/options vest in 48 equal monthly installments beginning April 5, 2026.

Key Details

• Transaction date: 2026-03-05; Filing date: 2026-03-09 (filed within the standard two business-day window).
• Transaction type/code: A (award/grant) — reported as a derivative acquisition at $0.00 for 240,000 shares.
• Shares owned after transaction: not specified in the Form 4 (beneficial ownership totals not provided in the published summary).
• Footnotes:
  • F1: Includes 13,702 shares acquired under the issuer’s Employee Stock Purchase Plan on November 20, 2025 (listed in the filing).
  • F2: The shares subject to the option/award vest in 48 equal monthly installments beginning April 5, 2026.
• No 10b5-1 plan or tax-withholding sale is indicated; this appears to be a standard equity compensation grant.

Context

• This is a compensation grant (an award of a derivative security), not an open-market purchase or sale — such grants are routine for executives and reflect compensation rather than an immediate bullish or bearish trading signal.
• Because the award vests over four years, the shares are not immediately tradable; watch future Form 4s for any exercises, sales, or tax-withholding transactions that would reflect actual changes in ownership or cash flows.